M 052
Alternative Names: AAV-GLA-S1S3; M-052Latest Information Update: 09 Feb 2023
Price :
$50 *
At a glance
- Originator M6P Therapeutics
- Class Gene therapies
- Mechanism of Action Alpha-galactosidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Fabry's disease
Most Recent Events
- 09 Feb 2023 M6P Therapeutics plans to file IND for Fabry's disease by Q1 2025 (M6P Therapeutics website, February 2023)
- 04 Feb 2021 M 052 is available for licensing as of 04 Feb 2021
- 04 Feb 2021 Preclinical trials in Fabry's disease in USA (Parenteral) before February 2021 (M6P Therapeutics pipeline, February 2021)